Neurofilament light as a blood biomarker for neurodegeneration in Down syndrome
Abstract Background Down syndrome (DS) may be considered a genetic form of Alzheimer’s disease (AD) due to universal development of AD neuropathology, but diagnosis and treatment trials are hampered by a lack of reliable blood biomarkers. A potential biomarker is neurofilament light (NF-L), due to i...
Main Authors: | Andre Strydom, Amanda Heslegrave, Carla M. Startin, Kin Y. Mok, John Hardy, Jurgen Groet, Dean Nizetic, Henrik Zetterberg, The LonDownS Consortium |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2018-04-01
|
Series: | Alzheimer’s Research & Therapy |
Subjects: | |
Online Access: | http://link.springer.com/article/10.1186/s13195-018-0367-x |
Similar Items
-
Saliva Neurofilament Light Chain Is Not a Diagnostic Biomarker for Neurodegeneration in a Mixed Memory Clinic Population
by: Helena Sophia Gleerup, et al.
Published: (2021-05-01) -
Validating the Cognitive Scale for Down Syndrome (CS-DS) to Detect Longitudinal Cognitive Decline in Adults With Down Syndrome
by: Carla M. Startin, et al.
Published: (2019-04-01) -
Plasma biomarkers for amyloid, tau, and cytokines in Down syndrome and sporadic Alzheimer’s disease
by: Carla M. Startin, et al.
Published: (2019-03-01) -
Plasma neurofilament light as a potential biomarker of neurodegeneration in Alzheimer’s disease
by: Piotr Lewczuk, et al.
Published: (2018-07-01) -
Dynamics of plasma biomarkers in Down syndrome: the relative levels of Aβ42 decrease with age, whereas NT1 tau and NfL increase
by: David Mengel, et al.
Published: (2020-03-01)